Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05212558
Other study ID # RHPT/0020/0061
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2, 2020
Est. completion date October 28, 2021

Study information

Verified date January 2022
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was designed to assess the effect of inspiratory and expiratory muscle training in the same cycle on respiratory muscle strength, pulmonary functions, perception of asthma symptoms in children with bronchial asthma. Fifty-one children with bronchial asthma were randomly allocated to the unloaded respiratory muscle training (Placebo training group; n = 17), inspiratory muscle training alone (inspiratory muscle training group; n = 17), or combined inspiratory and expiratory muscle training in the same cycle (combined training group; n = 17). All groups were assessed for respiratory muscle strength, pulmonary functions, and asthma symptoms.


Description:

Fifty-one children with bronchial asthma were recruited from King Khalid Hospital, Al-Kharj, Saudi Arabia. The study included children who had a confirmed diagnosis of bronchial asthma according to the Global Initiative for Asthma guidelines, aged 12-18 years, identified as being stable cases, had a baseline percent-predicted value of the peak expiratory flow rate of 60-80%, sustained stale doses of medications in the past three months. Children who had unstable asthma or exacerbated asthma symptoms, history of thoracic surgery, or cardiopulmonary comorbidities were excluded. Outcome measures 1. Respiratory muscle strength: assessed by measuring the maximal inspiratory and expiratory pressure using an electronic respiratory pressure meter. 2. Pulmonary function: The forced vital capacity (FVC), forced expiratory volume in the first second of expiration (FEV1), and FEV1/FVC ratio, were measured in a pulmonary function test through a spirometry analyzer. 3. Control of asthma symptoms: Asthma symptoms were assessed using a translated version of the asthma control test. All groups received the conventional respiratory re-training program, three times a week, for 12 weeks in succession. The placebo group additionally received unloaded respiratory muscle training, the inspiratory muscle training group received respiratory muscle training alone, and the combined group received combined inspiratory and expiratory muscle training in the same cycle. Interventions were conducted by a licensed physical therapist who had experience of more than 10 years of respiratory training.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date October 28, 2021
Est. primary completion date October 28, 2021
Accepts healthy volunteers No
Gender All
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria: - Confirmed diagnosis of asthma according to Global Initiative of Asthma guidelines. - Age between 12 and 18 years. - Clinically stable asthma. - Stable doses of medications in the last three months - A percent-predicted value of the peak expiratory flow rate of 60-80% - No activity limitation due to asthma Exclusion Criteria: - Unstable asthma - Exacerbation of asthma symptoms - History of thoracic surgery - Cognitive/behavioral problems - Cardiopulmonary co-morbidities

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Placebo respiratory muscle training
Unloaded respiratory muscle training plus conventional respiratory exercises
Inspiratory muscle training
Inspiratory muscle training plus conventional respiratory exercises
Combined inspiratory and expiratory muscle training
Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.

Locations

Country Name City State
Saudi Arabia Ragab K. Elnaggar Al Kharj Riyadh

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inspiratory muscle strength Inspiratory muscle strength was assessed by measuring the maximal inspiratory pressure (reflects the strength of the diaphragm and other inspiratory muscles) using an electronic respiratory pressure meter, according to the American Thoracic Society and European Respiratory Society standards. The highest value of three acceptable trials was documented and used for the subsequent analysis. The percent predicted maximal inspiratory pressure values (%) were calculated and used for statistical analysis. 2 months
Primary Expiratory muscle strength Expiratory muscle strength was assessed by measuring the maximal expiratory pressure (reflects the strength of the abdominal muscles and other expiratory muscles) using an electronic respiratory pressure meter, according to the American Thoracic Society and European Respiratory Society standards. The highest value of three acceptable trials was documented and used for the subsequent analysis. The percent predicted maximal inspiratory pressure values (%) were calculated and used for statistical analysis. 2 months
Primary Forced vital capacity Forced vital capacity, which is the amount of air that each participant was able to forcibly exhale from his/her lungs after taking the deepest breath they can, was measured in a pulmonary function test with a spirometry analyzer and expressed as a percentage of predicted values (%). Three trials were allowed and the best results were recorded. 2 months
Primary Forced expiratory volume in one second Forced expiratory volume in one second, which is the volume of air exhaled in the first second during forced exhalation after a maximal inspiration, was measured in a pulmonary function test with a spirometry analyzer and expressed as a percentage of predicted values (%). Three trials were allowed and the best results were recorded. 2 months
Primary Forced expiratory volume in one second / forced vital capacity Forced expiratory volume in one second / forced vital capacity, is the ratio of the forced expiratory volume in the first one second to the forced vital capacity of the lungs. 2 months
Secondary Asthma symptoms A translated version of the asthma control test was used to assess the degree of control over asthma symptoms. The test is patient-administered consists of 5 items. Each item has five possible responses (1: not controlled and 5: completely controlled). the test score ranges from 5 (inadequate control) to 25 (optimal control). 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT05088512 - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population